Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives (clinicaltrials.gov) - Oct 1, 2026 - P1 | N=148 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting
Enrollment open • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease
|